Abstract

The present disclosure provides a compound for use in therapeutic and/or prophylactic treatment of non-alcoholic steatohepatitis (NASH) and/or alcoholic steatohepatitis (ASH). The compound for use according to the invention, is an unsaturated fatty acid with an oxygen incorporated in the β-position, and further comprising an α-substituent. More particularly, the invention provides a compound for use in treatment of NASH and/or ASH, and a method using this, wherein the compound is of Formula (II), wherein R1, R2, R3, X, and Y are as defined in the specification; and wherein this compound may be administered alone or in combination with an additional active agent.

IPC Classes  ?

• A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

The present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of Formula (II): The present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of Formula (II): wherein R1, R2, R3, X and Y are as defined in the specification; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt. The present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of Formula (II): wherein R1, R2, R3, X and Y are as defined in the specification; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt. More particularly, the present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of Formula (I): The present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of Formula (II): wherein R1, R2, R3, X and Y are as defined in the specification; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt. More particularly, the present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of Formula (I): wherein R2, R3, and X, are as defined in the specification; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt. The present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of Formula (II): wherein R1, R2, R3, X and Y are as defined in the specification; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt. More particularly, the present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of Formula (I): wherein R2, R3, and X, are as defined in the specification; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt. Further, the present invention relates to a compound of Formula (I) for preventing and/or treating non-alcoholic steatohepatitis, wherein R2, R3 and X are as defined in the specification; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt.

IPC Classes  ?

• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61K 31/22 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

The present invention refers to a process for reducing the amount of undesired components in an oil composition, particularly in an oil composition comprising omega-3 polyunsaturated fatty acids. The process of the present invention provides efficient removal of undesired water-soluble (hydrophilic) components and undesired fat-soluble (lipophilic) components from an oil composition in order to obtain a purified concentrate, e.g. a highly purified concentrate enriched in omega-3 polyunsaturated fatty acids.

IPC Classes  ?

• C11B 3/00 - Refining fats or fatty oils
• A23D 9/00 - Other edible oils or fats, e.g. shortenings or cooking oils
• A23D 9/02 - Other edible oils or fats, e.g. shortenings or cooking oils characterised by the production or working-up
• A23K 20/158 - Fatty acidsFatsProducts containing oils or fats
• A23K 50/80 - Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
• A23L 5/20 - Removal of unwanted matter, e.g. deodorisation or detoxification
• A23L 33/12 - Fatty acids or derivatives thereof
• C11B 3/06 - Refining fats or fatty oils by chemical reaction with bases
• C11B 3/12 - Refining fats or fatty oils by distillation

Abstract

Compositions comprising 2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenyloxy)butanoic acid, an ester derivative, or a pharmaceutically acceptable salt thereof; a triglyceride; and a surfactant, as well as methods for their use. The present disclosure further relates to self-emulsifying drug delivery systems, such as SEDDS, SMEDDS, or SNEDDS comprising 2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenyloxy)butanoic acid.

IPC Classes  ?

• A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
• A61K 9/107 - Emulsions
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid

Abstract

The present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of Formula (II): or a pharmaceutically acceptable salt, solvate, or solvate of such a salt. More particularly, the present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of Formula (I): or a pharmaceutically acceptable salt, solvate, or solvate of such a salt. 3 and X are as defined in the specification; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt.

IPC Classes  ?

• A61K 31/10 - SulfidesSulfoxidesSulfones
• C07C 321/18 - Sulfides, hydropolysulfides, or polysulfides having thio groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton
• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61K 31/22 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

The present disclosure relates to compounds of the general formula (I): wherein R1, R2, R3, R4, R5, R6, and R7 may be chosen from different substituents; n is 0, 1, or 2; and X is a hydroxymethyl or a carboxylic acid or a derivative thereof, such as a carboxylate, such as a carboxylic ester, a glyceride, an anhydride, a phospholipid, a carboxamide, a phospholipid, or a prodrug thereof; or a pharmaceutically acceptable salt, solvate, solvate of such salt or a prodrug thereof. The present disclosure also relates to pharmaceutical compositions and lipid compositions comprising at least one compound according to the present disclosure, and to such compounds for use as medicaments or for use in therapy, in particular for the treatment of diseases related to metabolic diseases and liver diseases, such as non-alcoholic fatty liver disease and cholestasis diseases.

IPC Classes  ?

• C07C 63/64 - Monocyclic acids with unsaturation outside the aromatic ring
• C07C 63/04 - Monocyclic monocarboxylic acids

Abstract

The present disclosure provides a compound for use as an activator of enteroendocrine GLP-1 production, improving glycemic control, and treating inflammatory bowel disease, wherein the compound is a structurally modified unsaturated fatty acid with an α-substituent, either alone or in combination with one or more additional therapeutic agents.

IPC Classes  ?

• A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Abstract

The present disclosure provides a compound for use in therapeutic and/or prophylactic treatment of non-alcoholic steatohepatitis (NASH) and/or alcoholic steatohepatitis (ASH). The compound for use according to the invention, is an unsaturated fatty acid with an oxygen incorporated in the β-position, and further comprising an α-substituent. More particularly, the invention provides a compound for use in treatment of NASH and/or ASH, and a method using this, wherein the compound is of Formula (II), wherein RI, R2, R3, X, and Y are as defined in the specification; and wherein this compound may be administered alone or in combination with an additional active agent.

IPC Classes  ?

• A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Goods & Services

Excipients sold as a component ingredient of dietary and nutritional supplements

Abstract

The present disclosure relates to compounds of the general formula (I): wherein R1, R2, R3, R4, R5, R6, and R7 may be chosen from different substituents; n is 0, 1, or 2; and X is a hydroxymethyl or a carboxylic acid or a derivative thereof, such as a carboxylate, such as a carboxylic ester, a glyceride, an anhydride, a phospholipid, a carboxamide, a phospholipid, or a prodrug thereof; or a pharmaceutically acceptable salt, solvate, solvate of such salt or a prodrug thereof. The present disclosure also relates to pharmaceutical compositions and lipid compositions comprising at least one compound according to the present disclosure, and to such compounds for use as medicaments or for use in therapy, in particular for the treatment of diseases related to metabolic diseases and liver diseases, such as non-alcoholic fatty liver disease and cholestasis diseases.

IPC Classes  ?

• C07C 59/64 - Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/06 - Antihyperlipidemics
• C07C 63/04 - Monocyclic monocarboxylic acids
• C07C 63/64 - Monocyclic acids with unsaturation outside the aromatic ring
• C07C 65/21 - Compounds having carboxyl groups bound to carbon atoms of six-membered aromatic rings and containing any of the groups OH, O-metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
• C07C 65/28 - Compounds having carboxyl groups bound to carbon atoms of six-membered aromatic rings and containing any of the groups OH, O-metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups having unsaturation outside the aromatic rings
• C07C 65/32 - Compounds having carboxyl groups bound to carbon atoms of six-membered aromatic rings and containing any of the groups OH, O-metal, —CHO, keto, ether, groups, groups, or groups containing keto groups
• C07C 229/54 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
• C07C 233/54 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
• C07C 235/46 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
• C07C 317/44 - SulfonesSulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
• C07C 323/62 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton

Abstract

12345677 may be chosen from different substituents; n is 0, 1, or 2; and X is a hydroxymethyl or a carboxylic acid or a derivative thereof, such as a carboxylate, such as a carboxylic ester, a glyceride, an anhydride, a phospholipid, a carboxamide, a phospholipid, or a prodrug thereof; or a pharmaceutically acceptable salt, solvate, solvate of such salt or a prodrug thereof. The present disclosure also relates to pharmaceutical compositions and lipid compositions comprising at least one compound according to the present disclosure, and to such compounds for use as medicaments or for use in therapy, in particular for the treatment of diseases related to metabolic diseases and liver diseases, such as non-alcoholic fatty liver disease and cholestasis diseases.

IPC Classes  ?

• C07C 59/64 - Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
• C07C 63/04 - Monocyclic monocarboxylic acids
• C07C 63/64 - Monocyclic acids with unsaturation outside the aromatic ring
• C07C 65/21 - Compounds having carboxyl groups bound to carbon atoms of six-membered aromatic rings and containing any of the groups OH, O-metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
• C07C 65/28 - Compounds having carboxyl groups bound to carbon atoms of six-membered aromatic rings and containing any of the groups OH, O-metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups having unsaturation outside the aromatic rings
• C07C 65/32 - Compounds having carboxyl groups bound to carbon atoms of six-membered aromatic rings and containing any of the groups OH, O-metal, —CHO, keto, ether, groups, groups, or groups containing keto groups
• C07C 229/54 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
• C07C 233/54 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
• C07C 235/46 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
• C07C 317/44 - SulfonesSulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
• C07C 323/62 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/06 - Antihyperlipidemics

Abstract

The present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of Formula (II): or a pharmaceutically acceptable salt, solvate, or solvate of such a salt. More particularly, the present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of Formula (I): or a pharmaceutically acceptable salt, solvate, or solvate of such a salt. 3 and X are as defined in the specification; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt.

IPC Classes  ?

• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• C07C 59/60 - Unsaturated compounds containing ether groups, groups, groups, or groups the non-carboxylic part of the ether being unsaturated
• A61K 31/22 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

The present disclosure provides a compound for use as an activator of enteroendocrine GLP-1 production, improving glycemic control, and treating inflammatory bowel disease, wherein the compound is a structurally modified unsaturated fatty acid with an a-substituent, either alone or in combination with one or more additional therapeutic agents.

IPC Classes  ?

• A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 3/08 - Drugs for disorders of the metabolism for glucose homeostasis
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The present disclosure provides a compound for use as an activator of enteroendocrine GLP-1 production, improving glycemic control, and treating inflammatory bowel disease, wherein the compound is a structurally modified unsaturated fatty acid with an α-substituent, either alone or in combination with one or more additional therapeutic agents.

IPC Classes  ?

• A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 3/08 - Drugs for disorders of the metabolism for glucose homeostasis
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of Formula (II): or a pharmaceutically acceptable salt, solvate, or solvate of such a salt. More particularly, the present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of Formula (I): or a pharmaceutically acceptable salt, solvate, or solvate of such a salt. 3 and X are as defined in the specification; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt.

IPC Classes  ?

• A61K 31/10 - SulfidesSulfoxidesSulfones
• C07C 321/18 - Sulfides, hydropolysulfides, or polysulfides having thio groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton
• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61K 31/22 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

The present disclosure provides a compound for use in therapeutic and/or prophylactic treatment of non-alcoholic steatohepatitis (NASH) and/or alcoholic steatohepatitis (ASH). The compound for use according to the invention, is an unsaturated fatty acid with an oxygen incorporated in the ß-position, and further comprising an a-substituent. More particularly, the invention provides a compound for use in treatment of NASH and/or ASH, and a method using this, wherein the compound is of Formula (II), wherein R1, R2, R3, X, and Y are as defined in the specification; and wherein this compound may be administered alone or in combination with an additional active agent.

IPC Classes  ?

• A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The present disclosure provides a compound for use in therapeutic and/or prophylactic treatment of non-alcoholic steatohepatitis (NASH) and/or alcoholic steatohepatitis (ASH). The compound for use according to the invention, is an unsaturated fatty acid with an oxygen incorporated in the β-position, and further comprising an α-substituent. More particularly, the invention provides a compound for use in treatment of NASH and/or ASH, and a method using this, wherein the compound is of Formula (II), wherein R1, R2, R3, X, and Y are as defined in the specification; and wherein this compound may be administered alone or in combination with an additional active agent.

IPC Classes  ?

• A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
• A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Goods & Services

Excipients for use in the manufacture of pharmaceutical preparations and/or dietary supplements

Goods & Services

Dietetic foods, namely, gelatin capsules containing Omega-3 fish oil concentrate, for medicinal purposes.

Goods & Services

Excipients for use in the manufacture of pharmaceutical preparations and/or dietary supplements; Surfactants for industrial purposes; all of the aforementioned excluding pharmaceutical products for the topical treatment of nail fungus.

Goods & Services

Excipients for use in the manufacture of pharmaceutical preparations and/or dietary supplements; Surfactants for industrial purposes. Dietary and nutritional supplements; Dietary and nutritional supplements for endurance sports; Greases for medical purposes; medicinal oils; dietetic foods adapted for medical purposes; biological preparations for medical purposes; dietetic beverages adapted for medical purposes; dietetic substances adapted for medical use; nutritional supplements; appetite suppressants for medical purposes; dietary supplements for animals; Food supplements for medical purposes.

Goods & Services

Excipients for use in the manufacture of pharmaceutical preparations and/or dietary supplements Excipients sold as an ingredient of dietary and nutritional supplements; excipients sold as an ingredient of dietary and nutritional supplements for endurance sports; excipients sold as an ingredient of medicinal oils; excipients sold as an ingredient of dietetic foods, namely, omega 3 capsules, tablets, gels, chewables, smoothies, enteral feed formulas, liquid nutritive preparations for oral or tube feeding and nutritional bars with omega-3 formulation, adapted for medical purposes; excipients sold as an ingredient of biological preparations for the treatment or prevention of cancer, cachexia, concussion, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), rheumatoid arthritis, hypertriglyceridemia (HTG), metabolic syndrome, sarcopenia, chronic inflammatory diseases and diabetes; excipients sold as an ingredient of dietetic beverages adapted for nutritional support for the treatment or prevention of cancer, cachexia, concussion, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), rheumatoid arthritis, hypertriglyceridemia (HTG), metabolic syndrome, sarcopenia, chronic inflammatory diseases and diabetes; excipients sold as an ingredient of dietetic substances, namely, omega-3 concentrate adapted for medical use; excipients sold as an ingredient of nutritional supplements adapted for medical use; excipients sold as an ingredient of nutritional supplements; excipients sold as an ingredient of food supplements for medical purposes

Abstract

Compositions comprising 2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenyloxy)butanoic acid, an ester derivative, or a pharmaceutically acceptable salt thereof; a triglyceride; and a surfactant, as well as methods for their use. The present disclosure further relates to self-emulsifying drug delivery systems, such as SEDDS, SMEDDS, or SNEDDS comprising 2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenyloxy)butanoic acid.

IPC Classes  ?

• A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
• A61K 9/107 - Emulsions
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid

Goods & Services

Dietary and nutritional supplements; dietary and nutritional supplements for endurance sports; dietetic foods, namely, powdered nutritional supplement mix, drink mix and concentrate, adapted for medical purposes; dietetic beverages adapted for medical purposes; dietetic substances adapted for the treatment of fatty liver disease; food supplements for medical purposes

Abstract

The present invention refers to a process for reducing the amount of undesired components in an oil composition, particularly in an oil composition comprising omega-3 polyunsaturated fatty acids. The process of the present invention provides efficient removal of undesired water-soluble (hydrophilic) components and undesired fat-soluble (lipophilic) components from an oil composition in order to obtain a purified concentrate, e.g. a highly purified concentrate enriched in omega-3 polyunsaturated fatty acids.

IPC Classes  ?

• C11B 3/00 - Refining fats or fatty oils
• A23D 9/00 - Other edible oils or fats, e.g. shortenings or cooking oils
• A23D 9/02 - Other edible oils or fats, e.g. shortenings or cooking oils characterised by the production or working-up
• C11B 3/06 - Refining fats or fatty oils by chemical reaction with bases
• C11B 3/12 - Refining fats or fatty oils by distillation
• A23K 1/16 - supplemented with accessory food factors; Salt blocks
• A23K 1/18 - specially adapted for particular animals
• A23L 1/015 - Removal of unwanted matter, e.g. deodorisation, detoxification (A23L 1/211 takes precedence);;
• A23L 1/30 - containing additives (A23L 1/308 takes precedence);;

Goods & Services

Greases for medical purposes; medicinal oils; lotions for pharmaceutical purposes; pharmaceutical preparations for skin care; dietetic foods adapted for medical purposes; food for babies; biological preparations for medical purposes; dietetic beverages adapted for medical purposes; medical preparations for slimming purposes; medicines for dental purposes; medicines for human purposes; medicines for veterinary purposes; dietetic substances adapted for medical use; nutritional supplements; appetite suppressants for medical purposes; dietary supplements for animals. Edible fats; edible oils; milk products. Biscuits/cookies; goods made from biscuits/cookies; bread; pastries; high-protein cereal bars.

Goods & Services

Greases for medical purposes; medicinal oils; lotions for pharmaceutical purposes; pharmaceutical preparations for skin care; dietetic foods adapted for medical purposes; food for babies; biological preparations for medical purposes; dietetic beverages adapted for medical purposes; medical preparations for slimming purposes; medicines for dental purposes; medicines for human purposes; medicines for veterinary purposes; dietetic substances adapted for medical use; nutritional supplements; appetite suppressants for medical purposes; dietary supplements for animals. Edible fats; edible oils; milk products. Biscuits/cookies; goods made from biscuits/cookies; bread; pastries; high-protein cereal bars.

Goods & Services

Greases for medical purposes; medicinal oils; lotions for pharmaceutical purposes; pharmaceutical preparations for skin care; dietetic foods adapted for medical purposes; food for babies; biological preparations for medical purposes; dietetic beverages adapted for medical purposes; medical preparations for slimming purposes; medicines for dental purposes; medicines for human purposes; medicines for veterinary purposes; dietetic substances adapted for medical use; nutritional supplements; appetite suppressants for medical purposes; dietary supplements for animals. Edible fats; edible oils; milk products. Biscuits/cookies; goods made from biscuits/cookies; bread; pastries; high-protein cereal bars.

Goods & Services

(1) Medicinal oils and nutritional supplements, namely, oils derived from fish comprising omega-3 fatty acids, for the general maintenance and improvement of human health, and oils derived from fish comprising high concentrates of omega-3 fatty acids, for medical use, namely, for the prevention and treatment of cardiovascular and related diseases, all the aforesaid goods sold in bulk by the barrel for further processing and packing, for use as an ingredient in the nutritional and medical products of others; edible fats and edible oils, namely, fats and oils derived from fish comprising omega-3 fatty acids, for the general maintenance and improvement of human health, and fats and oils derived from fish comprising high concentrates of omega-3 fatty acids, for medical use, namely, for the prevention and treatment of cardiovascular and related diseases, all the aforesaid goods sold in bulk by the barrel for further processing and packing, for use as an ingredient in the nutritional and medical products of others. (2) Medicinal oils and nutritional supplements, namely, oils derived from fish comprising omega-3 fatty acids, for the general maintenance and improvement of human health, and oils derived from fish comprising high concentrates of omega-3 fatty acids, for medical use, namely, for the prevention and treatment of cardiovascular and related diseases, all the aforesaid goods sold in the form of capsules intended for consumers; edible fats and edible oils, namely, fats and oils derived from fish comprising omega-3 fatty acids, for the general maintenance and improvement of human health, and fats and oils derived from fish comprising high concentrates of omega-3 fatty acids, for medical use, namely, for the prevention and treatment of cardiovascular and related diseases, all the aforesaid goods sold in the form of capsules intended for consumers.

Goods & Services

(1) Medicinal oils and nutritional supplements, namely, oils derived from fish comprising omega-3 fatty acids, for the general maintenance and improvement of human health, and oils derived from fish comprising high concentrates of omega-3 fatty acids, for medical use, namely, for the prevention and treatment of cardiovascular and related diseases, all the aforesaid goods sold in bulk by the barrel for further processing and packing, for use as an ingredient in the nutritional and medical products of others, and in the form of capsules intended for consumers; edible fats and edible oils, namely, fats and oils derived from fish comprising omega-3 fatty acids, for the general maintenance and improvement of human health, and fats and oils derived from fish comprising high concentrates of omega-3 fatty acids, for medical use, namely, for the prevention and treatment of cardiovascular and related diseases, all the aforesaid goods sold in bulk by the barrel for further processing and packing, for use as an ingredient in the nutritional and medical products of others, and in the form of capsules intended for consumers.

Goods & Services

Medicinal oils and nutritional supplements, namely, oils derived from fish comprising omega-3 fatty acids, for the general maintenance and/or improvement of human health, and oils derived from fish comprising high concentrates of omega-3 fatty acids, for medical use, namely, for the prevention and/or treatment of cardiovascular and related diseases, all the aforesaid goods sold in bulk by the barrel for further processing and/or packing, or for use as an ingredient in the nutritional or medical products of others, or in the form of capsules intended for consumers Edible fats and edible oils, namely, fats and oils derived from fish comprising omega-3 fatty acids, for the general maintenance and/or improvement of human health, and fats and oils derived from fish comprising high concentrates of omega-3 fatty acids, for medical use, namely, for the prevention and/or treatment of cardiovascular and related diseases, all the aforesaid goods sold in bulk by the barrel for further processing and/or packing, or for use as an ingredient in the nutritional or medical products of others, or in the form of capsules intended for consumers

Goods & Services

Pharmaceutical products in the form of Omega-3 fatty acids.

Goods & Services

Pharmaceutical products in the form of unsaturated fatty acids.

Goods & Services

Pharmaceutical preparations; lipids for pharmaceutical purposes; substances with marine origin for pharmaceutical purposes.

Goods & Services

Pharmaceutical preparations; lipids for pharmaceutical purposes; substances with marine origin for pharmaceutical purposes.

Goods & Services

Pharmaceutical preparations; dietetic substances adapted for medical use; food supplements; vitamins.

Goods & Services

Pharmaceutical products in the form of omega-3 fatty acids.

Goods & Services

Pharmaceutical products in the form of Omega-3 fatty acids for the treatment of post myocardial infarction and hypertriglyceridaemia.